IP Library Granted Patent US 8,846,052
Granted Patent B2
US 8,846,052 · App. 12/990,597 · Granted Sep 30, 2014

Bacterial toxin vaccine

Inventors: Kazutoshi Sawada (Sodegaura, JP); Kazuya Yoshida (Ikoma, JP); Takeshi Matsui (Ikoma, JP)
Assignees: Idemitsu Kosan Co., Ltd.; National University Corporation Nara Institute of Science and Technology
C12N15/8258A61K2039/517A61K39/0258C07K14/25C07K14/245A61K39/00C07K2319/55
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,846,052
App. No.
12/990,597
Granted
Sep 30, 2014
Kind
B2
Abstract

A bacterial toxin protein such as a Shiga toxin protein is efficiently produced using plant cells. The plant cells are transformed using a DNA construct containing DNA encoding a hybrid protein in which the bacterial toxin proteins such as the Shiga toxin proteins are tandemly linked through a peptide having the following characteristics (A) and (B) to produce the bacterial toxin protein in the plant cells: (A) a number of amino acids is 12 to 30; and (B) a content of proline is 20 to 35%.

Claims (28)

1. A hybrid protein comprising:

(a) two or three toxin proteins selected from the group consisting of Shiga toxin proteins, cholera toxin proteins, Escherichia coli heat-labile toxin proteins and combinations thereof, and

(b) a peptide having the amino acid sequence represented by SEQ ID NO: 2, 82, or 84 or an amino acid sequence which has at least 90% identity to the amino acid sequence represented by SEQ ID NO: 2, 82, or 84 and which is tandemly linked to the C-terminus of each of the toxin proteins, wherein said hybrid protein causes an immune response when administered to an animal.

2. The hybrid protein of claim 1 , wherein two of the Shiga toxin proteins, cholera toxin proteins, or Escherichia coli heat-labile toxin proteins are tandemly linked through a peptide having the amino acid sequence represented by SEQ ID NO: 2.

3. The hybrid protein of claim 1 or claim 2 , wherein each of the toxin proteins is a Shiga toxin protein B subunit.

4. The hybrid protein of claim 1 , wherein each of the toxin proteins are Stx2e proteins.

5. The hybrid protein of claim 1 , wherein each of the toxin proteins are cholera toxin protein B subunits.

6. The hybrid protein of claim 1 , wherein each of the toxin proteins are Escherichia coli heat-labile toxin protein B subunits.

7. The hybrid protein of claim 2 , which comprises the amino acid sequence represented by SEQ ID NO: 10, 12, 14, or 16.

8. The hybrid protein of claim 1 , which comprises the amino acid sequence represented by SEQ ID NO: 86, 88, 90, 92, 94, 96, 98, or 100.

9. The hybrid protein of claim 1 , which further comprises a secretory signal peptide derived from a plant at the amino terminus of the hybrid protein.

10. The hybrid protein of claim 9 , which further comprises an endoplasmic reticulum retention signal peptide at the carboxyl terminus of the hybrid protein.

11. The hybrid protein of claim 1 , which further comprises a chloroplast transit signal peptide at the amino terminus of the hybrid protein.

12. A DNA construct comprising a nucleotide sequence encoding the hybrid protein of claim 1 .

13. The DNA construct of claim 12 , which comprises a nucleotide sequence having the nucleotide sequence represented by SEQ ID NO: 9, 11, 13, or 15.

14. The DNA construct of claim 12 , which comprises a nucleotide sequence having the nucleotide sequence represented by SEQ ID NO: 85, 87, 89, 91, 93, 95, 97, or 99.

15. The DNA construct of claim 12 , wherein the nucleotide sequence encoding a hybrid protein is operably-linked to a 5′-untranslated region of an alcohol dehydrogenase gene derived from a plant.

16. The DNA construct of claim 15 , wherein the 5′-untranslated region of an alcohol dehydrogenase gene derived from a plant is derived from Nicotiana tabacum.

17. The DNA construct of claim 16 , which comprises the nucleotide sequence represented by any one of SEQ ID NOS: 24 to 29.

18. The DNA construct of claim 16 , which comprises the nucleotide sequence represented by any one of SEQ ID NOS: 101 to 111.

19. A recombinant vector comprising the DNA construct of claim 12 .

20. A transformant transformed with the recombinant vector of claim 19 .

21. The transformant of claim 20 , which is a transformed plant cell or a transformed plant.

22. A peptide having the amino acid sequence represented by one of SEQ ID NO: 2, 82, or 84.

23. The hybrid protein of claim 1 , wherein the peptide has the sequence represented by SEQ ID NO: 2.

24. The hybrid protein of claim 1 , wherein the peptide has the sequence represented by SEQ ID NO: 82.

25. The hybrid protein of claim 1 , wherein the peptide has the sequence represented by SEQ ID NO: 84.

26. The hybrid protein of claim 1 , which causes an immune response when administered to pigs.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2010
From: SAWADA, KAZUTOSHI; YOSHIDA, KAZUYA AS REPRESENTED BY HEIR, YOSHIDA, MAYUMI; YOSHIDA, KAZUYA AS REPRESENTED BY HEIR, YOSHIDA, NOBUO; YOSHIDA, KAZUYA AS REPRESENTED BY HEIR, YOSHIDA, KYOKO; MATSUI, TAKESHI
To: IDEMITSU KOSAN CO., LTD.; NATIONAL UNIVERSITY CORPORATION NARA INSTITUTE OF SCIENCE AND TECHNOLOGY
Reel/Frame 025339/0046 →
Priority Claims (1)
JP 2008-120573 · May 2, 2008 · national
Continuity (1)
Related Publication 20110231960A1 · Sep 22, 2011